The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Subscribe To Our Newsletter & Stay Updated
